Found: 52
Select item for more details and to access through your institution.
Cytokine detection by ELISPOT: relevance for immunological studies in type 1 diabetes.
- Published in:
- Diabetes/Metabolism Research & Reviews, 2002, v. 18, n. 5, p. 367, doi. 10.1002/dmrr.320
- By:
- Publication type:
- Article
Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: an overview of rationale, preclinical evidence, and initial clinical data.
- Published in:
- Frontiers in Oncology, 2015, p. 1, doi. 10.3389/fonc.2015.00202
- By:
- Publication type:
- Article
Inhibition of immune checkpoints and Vascular Endothelial Growth Factor as combination therapy for cancer: an overview of rationale, preclinical evidence, and initial clinical data.
- Published in:
- Frontiers in Oncology, 2015, p. 1, doi. 10.3389/fonc.2015.00202
- By:
- Publication type:
- Article
Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy.
- Published in:
- Nature Communications, 2023, p. 1, doi. 10.1038/s41467-023-37230-4
- By:
- Publication type:
- Article
Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors.
- Published in:
- Current Oncology Reports, 2018, v. 20, n. 12, p. 1, doi. 10.1007/s11912-018-0738-2
- By:
- Publication type:
- Article
Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
- Published in:
- Cancer & Metastasis Reviews, 2017, v. 36, n. 1, p. 43, doi. 10.1007/s10555-017-9656-2
- By:
- Publication type:
- Article
Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.
- Published in:
- 2017
- By:
- Publication type:
- Erratum
A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 4, p. 551, doi. 10.1007/s10637-023-01374-3
- By:
- Publication type:
- Article
A phase I/II study of MCS110 with BRAF/MEK inhibition in patients with melanoma after progression on BRAF/MEK inhibition.
- Published in:
- Investigational New Drugs, 2023, v. 41, n. 3, p. 365, doi. 10.1007/s10637-023-01364-5
- By:
- Publication type:
- Article
PD-1 and PD-L1 Inhibition in the Treatment of Advanced Melanoma.
- Published in:
- Journal of OncoPathology, 2013, v. 1, n. 4, p. 83, doi. 10.13032/tjop.2052-5931.100066
- By:
- Publication type:
- Article
The Biology and Clinical Development of MEK Inhibitors for Cancer.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
A Phase II Trial of Sorafenib in Metastatic Melanoma with Tissue Correlates.
- Published in:
- PLoS ONE, 2010, v. 5, n. 12, p. 1, doi. 10.1371/journal.pone.0015588
- By:
- Publication type:
- Article
A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma.
- Published in:
- PLoS ONE, 2010, v. 5, n. 1, p. 1, doi. 10.1371/journal.pone.0008714
- By:
- Publication type:
- Article
Treatment for Advanced Melanoma: New Drugs, New Opportunities, New Challenges.
- Published in:
- 2013
- By:
- Publication type:
- Opinion
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 3, p. 1, doi. 10.1007/s00262-023-03623-z
- By:
- Publication type:
- Article
Ziv-aflibercept plus pembrolizumab in patients with advanced melanoma resistant to anti-PD-1 treatment.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 1, p. 1, doi. 10.1007/s00262-023-03593-2
- By:
- Publication type:
- Article
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 8, p. 2209, doi. 10.1007/s00262-021-02855-1
- By:
- Publication type:
- Article
Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies.
- Published in:
- Cancer Immunology, Immunotherapy, 2018, v. 67, n. 12, p. 1833, doi. 10.1007/s00262-018-2241-x
- By:
- Publication type:
- Article
Inhibition of both BRAF and MEK in BRAF mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties.
- Published in:
- Cancer Immunology, Immunotherapy, 2013, v. 62, n. 4, p. 811, doi. 10.1007/s00262-012-1389-z
- By:
- Publication type:
- Article
Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti–PD-1 Era.
- Published in:
- JAMA Network Open, 2022, v. 5, n. 8, p. e2225459, doi. 10.1001/jamanetworkopen.2022.25459
- By:
- Publication type:
- Article
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 425, doi. 10.1007/s10637-012-9862-2
- By:
- Publication type:
- Article
Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 8, p. 2627, doi. 10.1002/cam4.3789
- By:
- Publication type:
- Article
Automated Flow Synthesis of Tumor Neoantigen Peptides for Personalized Immunotherapy.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-019-56943-5
- By:
- Publication type:
- Article
New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy.
- Published in:
- Drug, Healthcare & Patient Safety, 2014, v. 6, p. 77, doi. 10.2147/DHPS.S39568
- By:
- Publication type:
- Article
Precision cancer medicine: Concepts, current practice, and future developments.
- Published in:
- Journal of Internal Medicine, 2023, v. 294, n. 4, p. 455, doi. 10.1111/joim.13709
- By:
- Publication type:
- Article
Phase II Trial of Dacarbazine and Thalidomide for the Treatment of Metastatic Melanoma.
- Published in:
- Chemotherapy (0009-3157), 2009, v. 55, n. 4, p. 221, doi. 10.1159/000219435
- By:
- Publication type:
- Article
Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 1, p. 183, doi. 10.1007/s00280-012-1995-7
- By:
- Publication type:
- Article
Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 Therapy.
- Published in:
- Frontiers in Oncology, 2019, p. N.PAG, doi. 10.3389/fonc.2019.00199
- By:
- Publication type:
- Article
Single-Step Synthesis of Atmospheric CO2 Sorbents through Radiation-Induced Graft Polymerization on Commercial-Grade Fabrics.
- Published in:
- Radiation Research, 2019, v. 192, n. 2, p. 219, doi. 10.1667/RR15362.1
- By:
- Publication type:
- Article
Correction to: Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Developing real-world comparators for clinical trials in chemotherapy-refractory patients with gastric cancer or gastroesophageal junction cancer.
- Published in:
- Gastric Cancer, 2020, v. 23, n. 1, p. 133, doi. 10.1007/s10120-019-01008-9
- By:
- Publication type:
- Article
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
- Published in:
- 2016
- By:
- Publication type:
- journal article
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Clinical Activity of Ipilimumab for Metastatic Uveal Melanoma.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 20, p. 3687, doi. 10.1002/cncr.28282
- By:
- Publication type:
- Article
Erratum to: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.
- Published in:
- 2017
- By:
- Publication type:
- Erratum
Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.
- Published in:
- Journal of Neuro-Oncology, 2016, v. 129, n. 3, p. 389, doi. 10.1007/s11060-016-2196-8
- By:
- Publication type:
- Article
Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge.
- Published in:
- Journal of Neuro-Oncology, 2016, v. 129, n. 3, p. 389, doi. 10.1007/s11060-016-2196-8
- By:
- Publication type:
- Article
Vemurafenib and radiation therapy in melanoma brain metastases.
- Published in:
- Journal of Neuro-Oncology, 2013, v. 113, n. 3, p. 411, doi. 10.1007/s11060-013-1127-1
- By:
- Publication type:
- Article
Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care.
- Published in:
- Oncology, 2017, v. 93, n. 3, p. 164, doi. 10.1159/000475715
- By:
- Publication type:
- Article
Enrollment in Clinical Trials Correlates with Improved Survival in Metastatic Melanoma.
- Published in:
- Oncology, 2011, v. 81, n. 5/6, p. 403, doi. 10.1159/000335000
- By:
- Publication type:
- Article
The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
- Published in:
- Oncologist, 2020, v. 25, n. 6, p. 505, doi. 10.1634/theoncologist.2019-0659
- By:
- Publication type:
- Article
Ipilimumab for Patients With Advanced Mucosal Melanoma.
- Published in:
- Oncologist, 2013, v. 18, n. 6, p. 726, doi. 10.1634/theoncologist.2012-0464
- By:
- Publication type:
- Article
Mucosal Melanomas: A Case-Based Review of the Literature.
- Published in:
- Oncologist, 2010, v. 15, n. 7, p. 772, doi. 10.1634/theoncologist.2010-0067
- By:
- Publication type:
- Article
Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas.
- Published in:
- Clinical Epigenetics, 2015, v. 7, n. 1, p. 1, doi. 10.1186/s13148-015-0091-3
- By:
- Publication type:
- Article
Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
- Published in:
- 2020
- By:
- Publication type:
- journal article